Trial Profile
A Bioequivalence and Food Effect Study in Healthy Subjects Comparing Baricitinib Suspension and Commercial Tablet Formulations
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2019
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis; Giant cell arteritis; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 04 Dec 2017 Status changed from recruiting to completed.
- 13 Jul 2017 New trial record